Sino Biopharmaceutical Limited (HKG:1177)

Sino Biopharmaceutical Balance Sheet

Financials in millions CNY. Fiscal year is January - December.

Assets

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun 30, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Cash & Equivalents	14,882	12,181	9,570	9,452	12,066	10,569
Short-Term Investments	-	414.83	220.64	1,553	-	569.5
Trading Asset Securities	12,695	10,366	5,028	3,113	4,855	4,656
Cash & Short-Term Investments	27,577	22,961	14,818	14,118	16,922	15,794
Cash Growth	39.12%	54.96%	4.96%	-16.57%	7.14%	-3.88%
Accounts Receivable	10,676	6,009	5,013	4,596	4,643	4,285
Other Receivables	465.48	2,091	1,787	1,602	1,575	1,164
Receivables	11,142	8,100	6,800	6,199	6,219	5,537
Inventory	1,968	2,257	2,373	1,993	2,329	1,938
Prepaid Expenses	3,352	1,147	694.17	582.57	465.69	234.13
Other Current Assets	-	-	-	912.71	-	-
Total Current Assets	44,039	34,465	24,685	23,806	25,935	23,503
Property, Plant & Equipment	10,071	10,233	10,288	9,912	9,251	8,516
Long-Term Investments	20,155	23,465	26,337	25,181	25,230	25,169
Goodwill	4,353	3,496	915.69	680.45	662.61	647.93
Other Intangible Assets	3,755	192.09	271.89	248.49	278.35	291.56
Long-Term Deferred Tax Assets	581	506.59	516.29	567.01	505.15	334.87
Long-Term Deferred Charges	-	3,364	1,873	1,980	973.49	772.46
Other Long-Term Assets	253.98	287.51	520.8	1,230	1,229	1,308
Total Assets	83,208	76,010	65,408	63,605	64,064	60,543

Liabilities

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun 30, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Accounts Payable	2,166	1,532	1,571	1,335	1,884	1,795
Accrued Expenses	-	10,319	7,651	6,716	6,299	5,146
Short-Term Debt	-	-	-	136.13	136.13	136.13
Current Portion of Long-Term Debt	8,670	8,395	7,602	11,136	9,663	6,521
Current Portion of Leases	11.39	23.29	28.33	71.49	60.43	64.47
Current Income Taxes Payable	706.02	696.15	318.2	271.87	107.46	101.17
Current Unearned Revenue	-	391.68	253.24	282.6	310.79	238.2
Other Current Liabilities	15,471	3,842	2,133	2,658	1,690	1,344
Total Current Liabilities	27,024	25,200	19,556	22,607	20,151	15,345
Long-Term Debt	8,430	7,584	1,997	1,074	3,934	5,213
Long-Term Leases	60.84	67.31	83.39	298.39	324.26	319.95
Long-Term Unearned Revenue	695.06	621.88	557.92	548.27	749.07	674.45
Long-Term Deferred Tax Liabilities	552.92	286.4	237.55	781.54	831.79	881.59
Other Long-Term Liabilities	200.99	164.76	201.9	125.46	131.08	380.78
Total Liabilities	36,963	33,924	22,634	25,435	26,121	22,814

Shareholders' Equity

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun 30, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Common Stock	412.47	413.67	414.38	414.62	414.9	415.44
Additional Paid-In Capital	-	12,334	12,421	12,443	12,484	12,578
Retained Earnings	-	24,953	25,281	23,649	28,358	27,215
Treasury Stock	-2,961	-2,951	-2,975	-1,770	-1,432	-689.35
Comprehensive Income & Other	35,117	-4,079	-3,180	-4,262	-10,078	-9,228
Total Common Equity	32,568	30,671	31,961	30,474	29,747	30,291
Minority Interest	13,677	11,415	10,813	7,695	8,197	7,438
Shareholders' Equity	46,245	42,086	42,774	38,170	37,944	37,729
Total Liabilities & Equity	83,208	76,010	65,408	63,605	64,064	60,543

Additional Metrics

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun 30, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Total Debt	17,171	16,070	9,711	12,716	14,118	12,254
Net Cash (Debt)	10,406	6,891	5,107	1,402	2,804	3,540
Net Cash Growth	32.27%	34.93%	264.34%	-50.00%	-20.81%	59.33%
Net Cash Per Share	0.58	0.38	0.28	0.08	0.15	0.18
Filing Date Shares Outstanding	17,841	17,892	17,924	18,347	18,468	18,699
Total Common Shares Outstanding	17,841	17,892	17,924	18,347	18,468	18,699
Working Capital	17,016	9,266	5,129	1,199	5,784	8,158
Book Value Per Share	1.83	1.71	1.78	1.66	1.61	1.62
Tangible Book Value	24,460	26,983	30,773	29,546	28,806	29,352
Tangible Book Value Per Share	1.37	1.51	1.72	1.61	1.56	1.57
Buildings	-	5,373	5,016	4,248	3,871	3,571
Machinery	-	8,861	8,433	7,628	6,692	6,132
Construction In Progress	-	1,750	1,701	1,686	1,804	1,426

Data Source: S&P Global Market Intelligence Last updated: Jun 30, 2026

Financial data is provided by S&P Global Market Intelligence and updates within hours after each earnings release, which is every six months for this company.

Update frequency:

Semi-annually

Last checked:

Aug 21, 2026

Data Sources Report a data error